Generic Watch
Track upcoming generic launches. When patents expire, generic competition typically reduces drug prices by 80-95%.
Expiring Within 3 Years
| Drug | Cost/Claim | Patent Expires | Time Left |
|---|---|---|---|
| Januvia Sitagliptin | $219.00 | Jul 17, 2026 | 3mo |
| Trintellix Vortioxetine | $278.00 | Sep 30, 2026 | 6mo |
| Entresto Sacubitril/Valsartan | $379.00 | Nov 11, 2026 | 7mo |
| Revlimid Lenalidomide | $12,786.00 | Mar 15, 2027 | 11mo |
| Pomalyst Pomalidomide | $17,250.00 | Apr 9, 2027 | 12mo |
| Trulicity Dulaglutide | $473.00 | Sep 18, 2027 | 1.4yr |
| Gilenya Fingolimod | $5,738.00 | Sep 22, 2027 | 1.4yr |
| Jakafi Ruxolitinib | $11,432.00 | Nov 16, 2027 | 1.6yr |
| Keytruda Pembrolizumab | $18,176.00 | Jun 28, 2028 | 2.3yr |
| Basaglar Insulin Glargine (biosimilar) | $130.00 | Dec 16, 2028 | 2.7yr |
Patent Protected (3+ Years)
| Drug | Cost/Claim | Patent Expires | Time Left |
|---|---|---|---|
| Repatha Evolocumab | $757.00 | Aug 27, 2029 | 3.4yr |
| Vraylar Cariprazine | $383.00 | Sep 17, 2029 | 3.4yr |
| Enbrel Etanercept | $1,726.00 | Nov 2, 2029 | 3.6yr |
| Venclexta Venetoclax | $6,784.00 | Apr 11, 2030 | 4.0yr |
| Trelegy Ellipta Fluticasone/Umeclidinium/Vilanterol | $380.00 | Sep 26, 2030 | 4.5yr |
| Harvoni Ledipasvir/Sofosbuvir | $24,958.00 | Oct 10, 2030 | 4.5yr |
| Dupixent Dupilumab | $2,819.00 | Mar 28, 2031 | 5.0yr |
| Breztri Aerosphere Budesonide/Glycopyrrolate/Formoterol | $305.00 | Jul 24, 2031 | 5.3yr |
| Ozempic Semaglutide | $685.00 | Sep 20, 2031 | 5.4yr |
| Fasenra Benralizumab | $2,836.00 | Nov 14, 2031 | 5.6yr |
| Tagrisso Osimertinib | $11,591.00 | Nov 13, 2032 | 6.6yr |
| Biktarvy Bictegravir/Emtricitabine/TAF | $3,746.00 | Feb 7, 2033 | 6.8yr |
| Rinvoq Upadacitinib | $3,498.00 | Aug 16, 2033 | 7.3yr |
| Skyrizi Risankizumab | $4,475.00 | Apr 23, 2035 | 9.0yr |
| Mounjaro Tirzepatide | $673.00 | May 13, 2036 | 10.1yr |